Sight Sciences Q4 revenue $20.4M (+7% YoY); guides 2026 revenue $82-88M

Sight Sciences, Inc.

Q4 2025 revenue $20.4M (+7% YoY); Interventional Glaucoma $19.7M (+5% YoY); Dry Eye $0.7M vs $0.3M.
Q4 net loss $4.2M ($0.08 loss per share) vs $11.8M loss in Q4 2024; full-year net loss $38.4M vs $51.5M.
Cash $92M at Dec 31, 2025; Q4 cash used only $0.4M; full-year cash used $28.4M.
FY 2026 guidance: revenue $82-88M (+6-14% YoY); Glaucoma $77-81M; Dry Eye $5-7M.
Operating expenses down 25% Q4 and 13% full-year; adjusted op ex guidance $93-96M for 2026.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.